Amy Bachrodt
Chief Financial OfficerMs. Amy Bachrodt is Chief Financial Officer of Lycia Therapeutics, Inc. from June 2026. Ms. Bachrodt was Senior Vice President of Finance of Maze Therapeutics, Inc. from May 2020 to May 2026. Ms. Bachrodt was Vice President of Finance of Maze Therapeutics, Inc. from 2022 to 2024. Ms. Bachrodt was Senior VP of Finance & CFO of Maze Therapeutics, Inc. Previously, Ms. Bachrodt served as Senior Director and Head of FP&A at Myovant Sciences Ltd., a clinical-stage biotechnology company, from April 2018 to May 2020. Ms. Bachrodt joined Lycia in June 2026. Prior to Myovant, she spent years at Genentech with broad exposure across the business, including roles of increasing leadership in Manufacturing, Product Development and eventually leading gross to net across Genentech’s Commercial portfolio. From September 2008 to April 2018, Ms. Bachrodt held roles of increasing responsibility at Genentech, Inc., a biotechnology company. Ms. Bachrodt began her career at Ernst & Young and spent her early career focused on fraud & forensic accounting working across a variety of industries. Ms. Bachrodt has a M.S. in Accounting from University of Notre Dame and a B.A. in Economics from Denison University in Ohio.
Positions
- Company NameLycia Therapeutics, Inc.Stock CodeLYCAPositionChief Financial OfficerColleagues
- AWAetna Wun TrombleyCEO, Secretary, President & Director
- WJWilliam JL RieflinIndependent Chair of the Board
- SSSteven StabenChief Scientific Officer
- CHChin Hyok LeeChief Medical Officer
- CRCarolyn R. BertozziFounder & Chair of Scientific Advisory Board
- LFLaurent FischerIndependent Director
- JPJane Pritchett V. HendersonIndependent Director
